Odyssey Therapeutics, Inc. (NASDAQ:ODTX – Get Free Report) Director Jeffrey Leiden acquired 5,000 shares of the company’s stock in a transaction that occurred on Friday, May 8th. The shares were bought at an average cost of $20.00 per share, for a total transaction of $100,000.00. Following the acquisition, the director directly owned 270,198 shares in the company, valued at $5,403,960. This represents a 1.89% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Odyssey Therapeutics Stock Performance
NASDAQ ODTX traded up $1.03 during trading hours on Monday, hitting $17.45. The company had a trading volume of 426,992 shares. Odyssey Therapeutics, Inc. has a 52 week low of $15.35 and a 52 week high of $20.30.
Further Reading
- Five stocks we like better than Odyssey Therapeutics
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for Odyssey Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odyssey Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
